+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-10-13Number of Pages: 246

Radiopharmaceutical Market (Radioisotope - Technetium-99, Gallium-67, Iodine-123, 18F, Rubidium-82, Yttrium-90, and Lutetium-177; End User - Hospitals, Ambulatory Surgical Centers, and Diagnostic Centers; Source - Nuclear Reactor and Cyclotrons; Application - Cardiology, Gastroenterology, Oncology (Brachytherapy), Nephrology, Neurology, and Immunology) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

Radiopharmaceutical Market: Snapshot

The global market for radiopharmaceuticals is poised for steady growth in the coming years, driven primarily by the rising use of radioisotopes for the treatment of various diseases, such as cancer, bone palliation, neurological disorders, and cardiovascular diseases. Around 35 million patients undergo treatment procedures for these diseases each year and this will continue to boost the demand for radiopharmaceuticals.

According to the Nuclear Energy Institute, radioisotopes are essential for biomedical research in order to cure AIDS, cancer, and Alzheimer’s disease. The World Nuclear Association states that around 10,000 hospitals across the world use radioisotopes in medicines and 90% of this is dedicated toward disease diagnosis.

The global radiopharmaceutical market was valued at US$4.7 bn in 2015 and is estimated to reach US$7.4 bn by 2024, expanding at a CAGR of 5.3% from 2016 to 2024.

Growing Incidence of Cancer Driving Demand for Most Radioisotopes

Based on radioisotope, the technetium-99 segment led the global radiopharmaceuticals market, accounting for a share of 50.3% in 2015. This can be attributed to the high availability of technetium-99 from molybdenum-99, which is generated through the decay of uranium radioactive raw material inside the sources.

The 18F radioisotope segment is expected to gain market share during the forecast period due to the increase in demand for cyclotron-based radioisotopes for nuclear medicine and the advancement of technological systems such as PET and SPECT. The demand for other radioisotopes such as lutetium-177, rubidium-87, and gallium-62 is also high due to the rising demand for radioisotopes for cancer treatment, the surge in the prevalence of cardiovascular diseases, and the detection of other infectious diseases. Based on application, oncology took the lead owing to the growing use of various radioisotopes in the treatment of different cancers.

Radiopharmaceutical products are used by various end users such as hospitals, ambulatory surgical centers, and diagnostic centers. Hospitals formed the leading segment of the market in terms of revenue in 2015 due to the growing usage of radiopharmaceutical. This can be attributed to technological advancements in various systems to cure cancer patients and the rise in favorable government reimbursement policies to help patients recover their costs and provide precaution against biohazards. The ambulatory surgical centers and diagnostic centers segments are expected to gain market share by 2024 due to the introduction of advanced imaging technologies such as SPECT and PET.

global radiopharmaceuticals market

 

Developing Regions to Witness Steady Growth despite Small Share in Global Market

The global radiopharmaceuticals market has been segmented into North America, Latin America, Asia Pacific, Europe, and the Middle East and Africa. North America led the radiopharmaceuticals market in 2015 in terms of revenue, with the U.S. emerging as the most prominent contributor to the radiopharmaceuticals market in North America. This can be attributed to the existence of several large nuclear reactors such as NRU, which accounts for a 30% to 40% share in the Mo-99 supply for the global production of nuclear medicine.

Europe is also expected to account for a significant share by 2024 due to the increase in the number of cyclotron installations for the production of radioisotopes used in the treatment of cancer and other diseases.

The Middle East and Africa is projected to account for a small share in the global market by 2024. However, growth in this market is likely to be attributed to the introduction of cyclotrons by the IBA Group and the setting up of new nuclear reactors such as ETRR-2 in South Africa for the production of radioisotopes.

Latin America is estimated to account for a meager share by the end of the forecast period. However, it continues to be driven by the increase in domestic collaborations with foreign radiopharmaceutical companies and major suppliers of radioactive raw materials and the establishment of hospitals and ambulatory surgical centers for cancer patients.

Prominent players operating in the radiopharmaceutical market include Advanced Accelerator Applications (AAA), Eckert & Ziegler, GE Healthcare, IBA Radiopharma Solutions, Lantheus Holdings, Inc., Mallinckrodt plc., Nordion, Inc., Siemens Healthineers, and Positron Corporation.

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Radiopharmaceutical Market

4. Market Overview
     4.1. Introduction
            4.1.1. Radioisotopes Definition
            4.1.2. Industry Evolution / Developments
     4.2.  Overview
     4.3. Key Market Indicators     
     4.4. Market Dynamics
            4.4.1. Drivers
            4.4.2. Restraints
            4.4.3. Opportunity
     4.5. Global Radiopharmaceutical Market Analysis and Forecasts, 2014–2024
            4.5.1. Market Revenue Projections (US$ Mn)
     4.7. Porter’s Five Force Analysis
     4.8. Value Chain Analysis
     4.9. Market Outlook
            4.9.1. FDA Approved Radiopharmaceutical Products, By Manufacturers & Trade Name 
            4.9.2. Market Size (US$ Mn) & Forecast, 2014-2024
            4.9.3. Market Share (%), By Segments, 2016
            4.9.4. Global Supply Demand Scenario, By Country, 2015
     4.10. Application of Radiopharmaceutical (Peptide Receptor Radionuclide Therapy (PRRT) and Brachytherapy

5. Global Radiopharmaceutical Market Analysis and Forecasts, By Radioisotopes 
     5.1. Introduction & Definition
     5.2. Key Findings / Developments
     5.3. Key Trends
     5.4. Market Value Analysis Forecast By Radioisotopes , 2014–2024
            5.4.1. Technetium-99
            5.4.2. Gallium-67
            5.4.3. Iodine-123
            5.4.4. Iodine-125
            5.4.5. 18F
            5.4.6. Rubidium-82
            5.4.7. Yttrium-90
            5.4.8. Lutetium-177
            5.4.9. Others
     5.5. Radioisotopes  Comparison Matrix
     5.6. Market Attractiveness By Radioisotopes 

6. Global Radiopharmaceutical Market Analysis and Forecasts, By Source 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Key Trends
     6.4. Market Value Analysis Forecast By Source , 2014–2024
            6.4.1. Nuclear Reactors
            6.4.2. Cyclotrons
     6.5. Source  Comparison Matrix
     6.6. Market Attractiveness By Source 

7. Global Radiopharmaceutical Market Analysis and Forecasts, By End-user  
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Key Trends
     7.4. Market Value Analysis Forecast By Application  , 2014–2024
            7.4.1. Cardiology
            7.4.2. Gastroenterology
            7.4.3. Oncology
                     7.4.3.1. Brachytherapy
                     7.4.3.2. Others
            7.4.4. Nephrology
            7.4.5. Neurology
            7.4.6. Immunology
            7.4.7. Others
     7.5. End-user   Comparison Matrix
     7.6. Market Attractiveness By End-user  

8. Global Radiopharmaceutical Market Analysis and Forecasts, By End-user  
     8.1. Introduction & Definition
     8.2. Key Findings / Developments
     8.3. Key Trends
     8.4. Market Value Analysis Forecast By End-user  , 2014–2024
            8.4.1. Hospitals
            8.4.2. Ambulatory Surgical Centers
            8.4.3. Diagnostic Centers
            8.4.4. Cancer Research Institutes
            8.4.5. Others
     8.5. End-user   Comparison Matrix
     8.6. Market Attractiveness By End-user  

9. Global Radiopharmaceutical Market Analysis and Forecasts, By Region
     9.1. Key Findings
     9.2. Policies and Regulations
     9.3. Market Value Analysis Forecast By Region
            9.3.1. North America 
            9.3.2. Europe 
            9.3.3. Asia Pacific 
            9.3.4. Latin America 
            9.3.5. Middle East and Africa 
     9.4. Market Attractiveness By Country/Region

10. North America Radiopharmaceutical Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
            10.1.2. Policies and Regulations
     10.2. Market Value Analysis Forecast By Radioisotopes , 2014–2024
            10.2.1. Technetium-99
            10.2.2. Gallium-67
            10.2.3. Iodine-123
            10.2.4. Iodine-125
            10.2.5. 18F
            10.2.6. Rubidium-82
            10.2.7. Yttrium-90
            10.2.8. Lutetium-177
            10.2.9. Others
     10.3. Market Value Analysis Forecast By Source , 2014–2024
            10.3.1. Nuclear Reactors
            10.3.2. Cyclotrons
     10.4. Market Value Analysis Forecast By Application  , 2014–2024
            10.4.1. Cardiology
            10.4.2. Gastroenterology
            10.4.3. Oncology
                     10.4.3.1. Brachytherapy
                     10.4.3.2. Others
            10.4.4. Nephrology
            10.4.5. Neurology
            10.4.6. Immunology
            10.4.7. Others
     10.5. Market Value Analysis Forecast By End-user  , 2014–2024
            10.5.1. Hospitals
            10.5.2. Ambulatory Surgical Centers
            10.5.3. Diagnostic Centers
            10.5.4. Cancer Research Institutes
            10.5.5. Others
     10.6. Market Value Analysis Forecast By Country , 2014–2024
            10.6.1. U.S.
            10.6.2. Canada
     10.7. Market Attractiveness Analysis 
            10.7.1. By Radioisotopes 
            10.7.2. By Source 
            10.7.3. By End-user  
            10.7.4. By End-user  
            10.7.5. By Country

11. Europe Radiopharmaceutical Market Analysis and Forecast
     11.1. Introduction
            11.1.1. Key Findings
            11.1.2. Policies and Regulations
     11.2. Market Value Analysis Forecast By Radioisotopes , 2014–2024
            11.2.1. Technetium-99
            11.2.2. Gallium-67
            11.2.3. Iodine-123
            11.2.4. Iodine-125
            11.2.5. 18F
            11.2.6. Rubidium-82
            11.2.7. Yttrium-90
            11.2.8. Lutetium-177
            11.2.9. Others
     11.3. Market Value Analysis Forecast By Source , 2014–2024
            11.3.1. Nuclear Reactors
            11.3.2. Cyclotrons
     11.4. Market Value Analysis Forecast By Application  , 2014–2024
            11.4.1. Cardiology
            11.4.2. Gastroenterology
            11.4.3. Oncology
                     11.4.3.1. Brachytherapy
                     11.4.3.2. Others
            11.4.4. Nephrology
            11.4.5. Neurology
            11.4.6. Immunology
            11.4.7. Others
     11.5. Market Value Analysis Forecast By End-user  , 2014–2024
            11.5.1. Hospitals
            11.5.2. Ambulatory Surgical Centers
            11.5.3. Diagnostic Centers
            11.5.4. Cancer Research Institutes
            11.5.5. Others
     11.6. Market Value Analysis Forecast By Country , 2014–2024
            11.6.1. U.K.
            11.6.2. Germany
            11.6.3. France
            11.6.4. Italy
            11.6.5. Spain
            11.6.6. Rest of Europe
     11.7. Market Attractiveness Analysis 
            11.7.1. By Radioisotopes 
            11.7.2. By Source 
            11.7.3. By End-user  
            11.7.4. By End-user  
            11.7.5. By Country

12. Asia Pacific Radiopharmaceutical Market Analysis and Forecast
     12.1. Introduction
            12.1.1. Key Findings
            12.1.2. Policies and Regulations
     12.2. Market Value Analysis Forecast By Radioisotopes , 2014–2024
            12.2.1. Technetium-99
            12.2.2. Gallium-67
            12.2.3. Iodine-123
            12.2.4. Iodine-125
            12.2.5. 18F
            12.2.6. Rubidium-82
            12.2.7. Yttrium-90
            12.2.8. Lutetium-177
            12.2.9. Others
     12.3. Market Value Analysis Forecast By Source , 2014–2024
            12.3.1. Nuclear Reactors
            12.3.2. Cyclotrons
     12.4. Market Value Analysis Forecast By Application , 2014–2024
            12.4.1. Cardiology
            12.4.2. Gastroenterology
            12.4.3. Oncology
                     12.4.3.1. Brachytherapy
                     12.4.3.2. Others
            12.4.4. Nephrology
            12.4.5. Neurology
            12.4.6. Immunology
            12.4.7. Others
     12.5. Market Value Analysis Forecast By End-user  , 2014–2024
            12.5.1. Hospitals
            12.5.2. Ambulatory Surgical Centers
            12.5.3. Diagnostic Centers
            12.5.4. Cancer Research Institutes
            12.5.5. Others
     12.6. Market Value Analysis Forecast By Country , 2014–2024
            12.6.1. India
            12.6.2. China
            12.6.3. Japan
            12.6.4. Australia
            12.6.5. Rest of Asia Pacific
     12.7. Market Attractiveness Analysis 
            12.7.1. By Radioisotopes 
            12.7.2. By Source 
            12.7.3. By End-user  
            12.7.4. By End-user  
            12.7.5. By Country

13. Latin America Radiopharmaceutical Market Analysis and Forecast
     13.1. Introduction
            13.1.1. Key Findings
            13.1.2. Policies and Regulations
     13.2. Market Value Analysis Forecast By Radioisotopes , 2014–2024
            13.2.1. Technetium-99
            13.2.2. Gallium-67
            13.2.3. Iodine-123
            13.2.4. Iodine-125
            13.2.5. 18F
            13.2.6. Rubidium-82
            13.2.7. Yttrium-90
            13.2.8. Lutetium-177
            13.2.9. Others
     13.3. Market Value Analysis Forecast By Source , 2014–2024
            13.3.1. Nuclear Reactors
            13.3.2. Cyclotrons
     13.4. Market Value Analysis Forecast By Application  , 2014–2024
            13.4.1. Cardiology
            13.4.2. Gastroenterology
            13.4.3. Oncology
                     13.4.3.1. Brachytherapy
                     13.4.3.2. Others
            13.4.4. Nephrology
            13.4.5. Neurology
            13.4.6. Immunology
            13.4.7. Others
     13.5. Market Value Analysis Forecast By End-user  , 2014–2024
            13.5.1. Hospitals
            13.5.2. Ambulatory Surgical Centers
            13.5.3. Diagnostic Centers
            13.5.4. Cancer Research Institutes
            13.5.5. Others
     13.6. Market Value Analysis Forecast By Country , 2014–2024
            13.6.1. Brazil
            13.6.2. Mexico
            13.6.3. Rest of Latin America
     13.7. Market Attractiveness Analysis 
            13.7.1. By Radioisotopes 
            13.7.2. By Source 
            13.7.3. By End-user  
            13.7.4. By End-user  
            13.7.5. By Country

14. Middle East and Africa Radiopharmaceutical Market Analysis and Forecast
     14.1. Introduction
            14.1.1. Key Findings
            14.1.2. Policies and Regulations
     14.2. Market Value Analysis Forecast By Radioisotopes , 2014–2024
            14.2.1. Technetium-99
            14.2.2. Gallium-67
            14.2.3. Iodine-123
            14.2.4. Iodine-125
            14.2.5. 18F
            14.2.6. Rubidium-82
            14.2.7. Yttrium-90
            14.2.8. Lutetium-177
            14.2.9. Others
     14.3. Market Value Analysis Forecast By Source , 2014–2024
            14.3.1. Nuclear Reactors
            14.3.2. Cyclotrons
     14.4. Market Value Analysis Forecast By Application  , 2014–2024
            14.4.1. Cardiology
            14.4.2. Gastroenterology
            14.4.3. Oncology
                     14.4.3.1. Brachytherapy
                     14.4.3.2. Others
            14.4.4. Nephrology
            14.4.5. Neurology
            14.4.6. Immunology
            14.4.7. Others
     14.5. Market Value Analysis Forecast By End-user  , 2014–2024
            14.5.1. Hospitals
            14.5.2. Ambulatory Surgical Centers
            14.5.3. Diagnostic Centers
            14.5.4. Cancer Research Institutes
            14.5.5. Others
     14.6. Market Value Analysis Forecast By Country , 2014–2024
            14.6.1. South Africa
            14.6.2. Saudi Arabia
            14.6.3. Rest of Middle East and Africa
     14.7. Market Attractiveness Analysis 
            14.7.1. By Radioisotopes 
            14.7.2. By Source 
            14.7.3. By End-user  
            14.7.4. By End-user  
            14.7.5. By Country

15. Competition Landscape
     15.1. Market Player – Competition Matrix (By Tier and Size of companies)
     15.2. Market Share Analysis By Company (2015)
     15.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            15.3.1. Advanced Accelerator Applications (AAA)
                     15.3.1.1. Overview
                     15.3.1.2. Financials
                     15.3.1.3. Recent Developments
                     15.3.1.4. Strategy
            15.3.2. Bayer AG
                     15.3.2.1. Overview
                     15.3.2.2. Financials
                     15.3.2.3. Recent Developments
                     15.3.2.4. Strategy
            15.3.3. Eckert & Ziegler 
                     15.3.3.1. Overview
                     15.3.3.2. Financials
                     15.3.3.3. Recent Developments
                     15.3.3.4. Strategy
            15.3.4. GE Healthcare 
                     15.3.4.1. Overview
                     15.3.4.2. Financials
                     15.3.4.3. Recent Developments
                     15.3.4.4. Strategy
            15.3.5. IBA Radiopharma Solutions 
                     15.3.5.1. Overview
                     15.3.5.2. Financials
                     15.3.5.3. Recent Developments
                     15.3.5.4. Strategy
            15.3.6. Lantheus Holdings, Inc. 
                     15.3.6.1. Overview
                     15.3.6.2. Financials
                     15.3.6.3. Recent Developments
                     15.3.6.4. Strategy
            15.3.7. Mallinckrodt plc. 
                     15.3.7.1. Overview
                     15.3.7.2. Financials
                     15.3.7.3. Recent Developments
                     15.3.7.4. Strategy
            15.3.8. Nordion, Inc. 
                     15.3.8.1. Overview
                     15.3.8.2. Financials
                     15.3.8.3. Recent Developments
                     15.3.8.4. Strategy
            15.3.9. Positron Corporation 
                     15.3.9.1. Overview
                     15.3.9.2. Financials
                     15.3.9.3. Recent Developments
                     15.3.9.4. Strategy
            15.3.10. Siemens Healthineers
                     15.3.10.1. Overview
                     15.3.10.2. Financials
                     15.3.10.3. Recent Developments
                     15.3.10.4. Strategy

 

List of Figures

FIG. 1 Global Radiopharmaceutical Market Size (US$ Mn) Forecast, 2014–2024
FIG. 3 Market Value Share, by Source (2016)
FIG. 5 Market Value Share, by End-user (2016)
FIG. 2 Market Value Share, by Radioisotope (2016)
FIG. 4 Market Value Share, by Application (2016)
FIG. 6 Global Radiopharmaceutical Market Value Share Analysis, by Radioisotope, 2016 and 2024
FIG. 7 Global Technetium-99 Market Revenue 
FIG. 8 Global Gallium-67 Market Revenue 
FIG. 9 Global Iodine-123 Market Revenue 
FIG. 10 Global 18F Market Revenue (US$ Mn), 
FIG. 11 Global Rubidium-82 Market Revenue 
FIG. 12 Global Yttrium-90 Market Revenue (US$ Mn), 2014–2024
FIG. 13 Global Lutetium-177 Market Revenue 
FIG. 14 Global Iodine-125 Market Revenue (US$ Mn), 2014–2024
FIG. 15 Global Other Radioisotope Market Revenue (US$ Mn), 2014–2024
FIG. 16 Global Radiopharmaceutical Market Attractiveness Analysis, by Radioisotope, 2016-2024
FIG. 17 Global Radiopharmaceutical Market Value Share Analysis, by Source, 2016 and 2024
FIG. 18 Global Nuclear Reactor Market Revenue 
FIG. 19 Global Cyclotrons Market Revenue (US$ Mn), 2014–2024
FIG. 20 Global Radiopharmaceutical Market Attractiveness Analysis, by Source 2016 and 2024
FIG. 21 Global Radiopharmaceutical Market Value Share Analysis, by Application, 2016 and 2024
FIG. 22 Global Radiopharmaceutical Market Value Share Analysis, by Oncology Application, 2016 and 2024
FIG. 23 Global Cardiology Market Revenue 
FIG. 24 Global Gastroenterology Market Revenue 
FIG. 25 Global Oncology Market Revenue 
FIG. 26 Global Nephrology Market Revenue (US$ Mn), 
FIG. 27 Global Neurology Market Revenue 
FIG. 28 Global Immunology Market Revenue (US$ Mn), 2014–2024
FIG. 29 Global Others Market Revenue (US$ Mn), 2014–2024
FIG. 30 Global Brachytherapy Market Revenue 
FIG. 31 Global Others Market Revenue (US$ Mn), 2014–2024
FIG. 32 Global Radiopharmaceutical Market Attractiveness Analysis, by Application, 2016-2024
FIG. 33 Global Radiopharmaceutical Market Value Share Analysis, by End-user, 2016 and 2024
FIG. 34 Global Hospitals Market Revenue (US$ Mn), 2014–2024
FIG. 35 Global Ambulatory Surgical Center Market Revenue (US$ Mn), 2014–2024
FIG. 36 Global Diagnostic Centers Market Revenue 
FIG. 37 Global Others Market Revenue (US$ Mn), 
FIG. 38 Global Other End user Market Revenue 
FIG. 39 Global Radiopharmaceutical Market Attractiveness Analysis, by End-user, 2016-2024
FIG. 40 Global Radiopharmaceutical Market Value Share Analysis, by Region, 2016 and 2024
FIG. 41 Global Radiopharmaceutical Market Attractiveness Analysis, by Region, 2016-2024
FIG. 42 North America Radiopharmaceutical Market Size
FIG. 43 North America Market Attractiveness Analysis,
FIG. 44 North America Market Value Share Analysis By Country, 2016 and 2024
FIG. 45 North America Market Value Share Analysis Source, 2016 and 2024
FIG. 46 North America Market Value Share Analysis by Source, 2016 and 2024
FIG. 47 North America Radiopharmaceuticals Market Value Share Analysis, by Application, 2016 and 2024
FIG. 48 North America Radiopharmaceuticals Market Value Share Analysis, by Oncology Application, 2016 and 2024
FIG. 49 North America Market Value Share Analysis by End-user, 2016 and 2024
FIG. 50 North America Market Attractiveness Analysis by Radioisotope, 2016-2024
FIG. 51 North America Market Attractiveness Analysis by Source, 2016-2024
FIG. 52 North America Market Attractiveness Analysis by Application, 2016-2024
FIG. 53 North America Market Attractiveness Analysis by End –user, 2016-2024
FIG. 54 Europe Radiopharmaceutical Market Size (US$ Mn) Forecast, 2014–2024
FIG. 55 Europe Market Attractiveness Analysis, by Country, 2016–2024
FIG. 56 Europe Market Value Share Analysis, by Country, 2016 and 2024
FIG. 57 Europe Market Value Share Analysis, by Radioisotope, 2016 and 2024
FIG. 58 Europe Market Value Share Analysis, by Source, 2016 and 2024
FIG. 59 Europe Radiopharmaceuticals Market Value Share Analysis, by Application, 2016 and 2024
FIG. 60 Europe Radiopharmaceuticals Market Value Share Analysis, by Oncology Application, 2016 and 2024
FIG. 61 Europe Market Value Share Analysis, by End-user, 2016 and 2024
FIG. 62 North America Market Attractiveness Analysis by Radioisotope, 2016-2024
FIG. 63 North America Market Attractiveness Analysis by Source, 2016-2024
FIG. 64 North America Market Attractiveness Analysis by Application, 2016-2024
FIG. 65 North America Market Attractiveness Analysis by End –user, 2016-2024
FIG. 66 Asia Pacific Radiopharmaceutical Market Size
FIG. 67 Asia Pacific Radiopharmaceutical Market Attractiveness Analysis, by Country, 2016–2024
FIG. 68 Asia Pacific Radiopharmaceutical Market Value Share Analysis, by Country, 2016 and 2024
FIG. 69 Asia Pacific Radiopharmaceutical Market Value Share Analysis, by Radioisotope, 2016 and 2024
FIG. 70 Asia Pacific Radiopharmaceutical Market Value Share Analysis, by Source, 2016 and 2024
FIG. 71 Asia Pacific Market Value Share Analysis, by Application, 2016 and 2024
FIG. 72 Asia Pacific Market Value Share Analysis, by Oncology Application, 2016 and 2024
FIG. 73 Asia Pacific Radiopharmaceutical Market Value Share Analysis, by End-user, 2016 and 2024
FIG. 74 Asia Pacific Market Attractiveness Analysis by Radioisotope, 2016-2024
FIG. 75 Asia Pacific Market Attractiveness Analysis by Source, 2016-2024
FIG. 76 Asia Pacific Market Attractiveness Analysis by Application, 2016-2024
FIG. 77 Asia Pacific Market Attractiveness Analysis by End –user, 2016-2024
FIG. 78 Latin America Radiopharmaceutical Market Size (US$ Mn) Forecast, 2014–2024
FIG. 79 Latin America Market Attractiveness Analysis, by Country, 2016–2024
FIG. 80 Latin America Radiopharmaceutical Market Value Share Analysis, by Country, 2016 and 2024
FIG. 81 Latin America Market Value Share Analysis, by Radioisotope, 2016 and 2024
FIG. 82 Latin America Market Value Share Analysis, by Source, 2016 and 2024
FIG. 83 Latin America Market Value Share Analysis, by Application, 2016 and 2024
FIG. 84 Latin America Market Value Share Analysis, by Oncology Application, 2016 and 2024
FIG. 85 Latin America Market Value Share Analysis, by End-user, 2016 and 2024
FIG. 86 Latin America Market Attractiveness Analysis by Radioisotope, 2016-2024
FIG. 87 Latin America Market Attractiveness Analysis by Source, 2016-2024
FIG. 88 Latin America Market Attractiveness Analysis by Application, 2016-2024
FIG. 89 Latin America Market Attractiveness Analysis by End –user, 2016-2024
FIG. 90 Middle East & Africa Radiopharmaceutical Market Size (US$ Mn) Forecast, 2014–2024
FIG. 91 Middle East & Africa Radiopharmaceutical Market Attractiveness Analysis, by Country, 2016–2024
FIG. 92 Middle East & Africa Radiopharmaceutical Market Value Share Analysis, by Country, 2016 and 2024
FIG. 93 Middle East & Africa Radiopharmaceutical Market Value Share Analysis, by Radioisotope, 2016 and 2024
FIG. 94 Middle East & Africa Market Value Share Analysis,
FIG. 95 Middle East and Africa Market Value Share Analysis, by Application, 2016 and 2024
FIG. 96 Middle East and Africa Market Value Share Analysis, by Oncology Application, 2016 and 2024
FIG. 97 Middle East & Africa Radiopharmaceutical Market Value Share Analysis, by End-user, 2016 and 2024
FIG. 98 Middle East and Africa Market Attractiveness Analysis by Radioisotope, 2016-2024
FIG. 99 Middle East and Africa Market Attractiveness Analysis by Source, 2016-2024
FIG. 100 Middle East and Africa Market Attractiveness Analysis by Application, 2016-2024
FIG. 101 Middle East and Africa Market Attractiveness Analysis by End –user, 2016-2024
FIG. 102 Global Radiopharmaceutical Market Share Analysis, by Company (2015)

List of Tables

Table 1: Global Radiopharmaceutical Market Size (US$ Mn) Forecast, by Radioisotope, 2014–2024
Table 2: Global Radiopharmaceutical Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 3: Global Radiopharmaceutical Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 4: Global Radiopharmaceutical Market Size (US$ Mn) Forecast, by Oncology Application, 2014–2024
Table 5: Global Radiopharmaceutical Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 6: Global Radiopharmaceutical Market Size (US$ Mn) Forecast, by Region, 2014–2024
Table 7: North America Radiopharmaceutical Market Size (US$ Mn) Forecast, By Country, 2014–2024
Table 8: North America Radiopharmaceutical Market Size (US$ Mn) Forecast, by Radioisotope, 2014–2024
Table 9: North America Radiopharmaceutical Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 10: North America Radiopharmaceuticals Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 11: North America Radiopharmaceuticals Market Size (US$ Mn) Forecast, by Oncology Application, 2014–2024
Table 12: North America Radiopharmaceutical Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 13: Europe Radiopharmaceutical Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 14: Europe Radiopharmaceutical Market Size (US$ Mn) Forecast, by Radioisotope, 2014–2024
Table 15: Europe Radiopharmaceutical Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 16: Europe Radiopharmaceuticals Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 17: Europe Radiopharmaceuticals Market Size (US$ Mn) Forecast, by Oncology Application, 2014–2024
Table 18: Europe Radiopharmaceutical Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 19: Asia Pacific Radiopharmaceutical Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 20: Asia Pacific Radiopharmaceutical Market Size (US$ Mn) Forecast, by Radioisotope, 2014–2024
Table 21: Asia Pacific Radiopharmaceutical Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 22: Asia Pacific Radiopharmaceutical Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 23: Asia Pacific Radiopharmaceutical Market Size (US$ Mn) Forecast, by Oncology Application, 2014–2024
Table 24: Asia Pacific Radiopharmaceutical Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 25: Latin America Radiopharmaceutical Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 26: Asia Pacific Radiopharmaceutical Market Size (US$ Mn) Forecast, by Radioisotope, 2014–2024
Table 27: Latin America Radiopharmaceutical Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 28: Latin America Radiopharmaceutical Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 29: Latin America Radiopharmaceutical Market Size (US$ Mn) Forecast, by Oncology Application, 2014–2024
Table 30: Latin America Radiopharmaceutical Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 31: Middle East & Africa Radiopharmaceutical Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 32: Asia Pacific Radiopharmaceutical Market Size (US$ Mn) Forecast, by Radioisotope, 2014–2024
Table 33: Middle East & Africa Radiopharmaceutical Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 34: Middle East and Africa Radiopharmaceutical Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 35: Middle East and Africa Radiopharmaceutical Market Size (US$ Mn) Forecast, by Oncology Application, 2014–2024
Table 36: Middle East & Africa Radiopharmaceutical Market Size (US$ Mn) Forecast, by End-user, 2014–2024

 

Radiopharmaceutical Market: Scope and Trends

This report on the radiopharmaceutical market analyzes the current and future scenario of the global market. Increase in incidence of various diseases, development of new sources for radioisotope production, and rise in demand for nuclear medicine are boosting the radiopharmaceutical market. Increase in incidence of cancer and cardiovascular diseases, growth in awareness about effective use of radiopharmaceuticals, and rise in preference for SPECT and PET scans are some of the factors expected to drive the growth of the global radiopharmaceutical market during the forecast period.

The radiopharmaceutical market report comprises an elaborate executive summary, which includes market snapshot that provides information about various segments. It also provides information and data analysis of the global market with respect to the segments based on radioisotopes, source, end-user, and geography. A detailed qualitative analysis of drivers and restraints, and opportunities has been provided in the market overview section. Additionally, the section comprises Porters Five Forces Analysis to help understand the competitive landscape in the market. This section also provides market attractiveness analysis in terms of geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global radiopharmaceutical market.

Radiopharmaceutical Market: Segmentation

Based on radioisotope, the market has been segmented into Technetium-99, Lutetium-177, Rubidium-87, Iodine-123, Yttrium-90, and Gallium-62. Technetium-99 is the most widely used radioisotope across the globe; around 70% of radiopharmaceutical companies depend on Mo-99 to produce Technetium-99, as per the World Nuclear Association. The market segments have been analyzed based on available approved products, cost-effectiveness, and preference for technological systems by physicians and patients. The market size and forecast for each of these segments have been provided for the period from 2014 to 2024, along with their respective CAGRs for the forecast period from 2016 to 2024, considering 2015 as the base year.

Based on source, the radiopharmaceutical market has been segmented into two major categories: nuclear reactors and cyclotrons. The market segments have been extensively analyzed based on increase in demand for radioisotopes for nuclear medicines, availability of radioisotopes and raw materials, radioisotopes short half-life and number of production units used for production of radioisotopes. Different types of end-user utilize radiopharmaceutical products to treat diseases either through imaging techniques or the therapeutics method.

Under the end-user segment, hospitals plays a major role followed by ambulatory surgical centers, diagnostic centers, and others (such as universities, research laboratories, and pathology labs). The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2014 to 2024. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2016 to 2024, considering 2015 as the base year. Application segment signifies the usage of radiopharmaceutical products through different disease indication such as oncology, cardiology, neurology, nephrology, gastroenterology, immunology and others. Oncology segment is the dominant sector which emphasizes the use of different radioisotopes for treating various cancers and overcome the side effects of therapeutics. Brachytherapy is a sub segment of oncology application which signifies the methods of treating cancer through implants, surgery or radiation technology. The segment is expected to have a significant growth during the forecast period. 

Geographically, the global radiopharmaceutical market has been categorized into five major regions and the key countries in the respective region: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, Japan, China, Australia, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, Saudi Arabia, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2014 to 2024, along with their respective CAGRs for the forecast period from 2016 to 2024, considering 2015 as the base year.

Radiopharmaceutical Market: Competitive Landscape

The report also profiles major players in the global radiopharmaceutical market based on various attributes such as company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments. Major players profiled in this report include Advanced Accelerator Applications (AAA), Eckert & Ziegler, GE Healthcare, IBA Radiopharma Solutions, Lantheus Holdings, Inc., Mallinckrodt plc., Nordion, Inc., Siemens Healthineers, and Positron Corporation.

The global radiopharmaceutical market has been segmented as follows:

Global Radiopharmaceutical Market, by Radioisotope

  • Technetium-99
  • Gallium-67
  • Iodine-123
  • 18F
  • Rubidium-82
  • Yttrium-90
  • Lutetium-177

Global Radiopharmaceutical Market, by Source

  • Nuclear Reactors
  • Cyclotrons

Global Radiopharmaceutical Market, by End-user

  • Hospitals
  • Ambulatory Surgical Centers
  • Diagnostic Centers
  • Others

Global Radiopharmaceutical Market, by Application

  • Cardiology
  • Gastroenterology
  • Oncology
  • Brachytherapy
  • Others
  • Nephrology
  • Neurology
  • Immunology
  • Others

Global Radiopharmaceutical Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East & Africa


 
 
Back To Top